The board of directors of Sino Biopharmaceutical Limited announced that "Sitagliptin Phosphate and Metformin Hydrochloride Sustained-release Tablets has obtained drug registration certificate granted by the National Medical Products Administration of the PRC. The product was filed as a Chemicals Category 3 drug and is deemed to have passed the Consistency of Quality and Efficacy Evaluation for Generic Drugs, being the first generic drug of its kind that has been approved for marketing in the PRC. Sitagliptin Phosphate and Metformin Hydrochloride Sustained-release Tablets are indicated for adults with type 2 diabetes who are receiving treatments in the combination of sitagliptin and metformin.

Sitagliptin phosphate is an oral, highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor and metformin is a first-line drug currently recommended by diabetes medication guidelines. As the duration of treatment increases, the control rate of blood glucose will gradually decrease. Studies have shown that the combination of sitagliptin phosphate and the traditional hypoglycaemic drug metformin can improve the control rate of blood glucose without increasing adverse effects.

The combination of sitagliptin and metformin is recommended by both domestic and international treatment guidelines.